SABCS 2024 Highlights in HR+ BC

CE / CME

Advances in the Evolving Treatment Landscape for HR+ Breast Cancer: Highlights From SABCS 2024

Nurse Practitioners: 0.25 Nursing contact hours, includes 0.25 hour of pharmacotherapy credit

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

Released: February 20, 2025

Expiration: August 19, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

In the phase III EMBER-3 trial comparing imlunestrant, imlunestrant plus abemaciclib, or standard-of-care (SoC) endocrine therapy (ET) with fulvestrant or exemestane in patients with hormone receptor (HR)–positive/HER2-negative advanced breast cancer (ABC) or metastatic breast cancer (MBC) and disease progression on an aromatase inhibitor (AI) treatment with or without a CDK4/6 inhibitor (CDK4/6i), which of the following accurately reflects the median progression-free survival (mPFS) outcomes with imlunestrant plus abemaciclib vs imlunestrant alone in the intention-to-treat (ITT) and ESR1-mutant populations?